The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Growth In Market Value Is Anticipated For The Chemotherapy-Induced Neutropenia Treatment Market Between 2026 And 2030?
The chemotherapy-induced neutropenia treatment market size has shown significant expansion in recent years. It is anticipated to grow from $0.62 billion in 2025 to $0.65 billion in 2026, registering a compound annual growth rate (CAGR) of 5.3%. This historical growth can be attributed to several factors including an elevated incidence of chemotherapy-induced neutropenia, the broader implementation of aggressive cancer treatment protocols, the accessibility of colony-stimulating factors, advancements in clinical monitoring practices, and the increasing number of oncology treatment facilities.
The chemotherapy-induced neutropenia treatment market is anticipated to experience substantial expansion in the coming years. This market is projected to reach a valuation of $0.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This projected growth throughout the forecast period stems from factors such as the increasing adoption of long-acting growth factors, a rising focus on outpatient neutropenia management, the expansion of biosimilar g-csf usage, growing investment in infection prevention strategies, and advancements in immunomodulatory therapies. Key trends anticipated during this period encompass the increasing adoption of prophylactic g-csf therapy, a rising use of early intervention treatment models, a growing emphasis on infection risk reduction, the expansion of personalized neutropenia management, and enhanced monitoring of white blood cell levels.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What Are The Main Drivers Accelerating The Growth Of The Chemotherapy-Induced Neutropenia Treatment Market?
The increasing prevalence of cancer is anticipated to drive the expansion of the chemotherapy-induced neutropenia treatment market in the coming years. Cancer is identified as a class of conditions marked by the uncontrolled proliferation and spread of abnormal cells within the body. The escalation in cancer diagnoses stems from the aging demographic, as older individuals face a greater likelihood of developing cancer due to accumulated genetic mutations and a decline in immune function over time. Chemotherapy-induced neutropenia treatment assists in cancer management by mitigating infection risks through bolstering immune defenses, thereby allowing patients to maintain their chemotherapy regimens with less frequent breaks. Furthermore, it improves therapeutic results by reducing adverse events, consequently elevating overall patient safety and their quality of life. For instance, in July 2024, as reported by the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Consequently, the growing incidence of cancer is a key driver for the chemotherapy-induced neutropenia treatment market.
Which Segment-Based Categories Are Covered In The Chemotherapy-Induced Neutropenia Treatment Market?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented –
1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy
Which Trends Are Expected To Shape The Chemotherapy-Induced Neutropenia Treatment Market?
Leading companies in the chemotherapy-induced neutropenia treatment market are actively working on developing and securing approvals for innovative products, particularly long-acting formulations, to enhance patient convenience, reduce the frequency of dosing, and improve treatment adherence. Such long-acting formulations represent drug preparations engineered to slowly release active ingredients over an extended period, thereby reducing the necessity for frequent administration. For instance, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, an innovative, ready-to-use on-body injector. This specific device, which incorporates a long-acting formulation, automatically delivers pegfilgrastim approximately 27 hours following chemotherapy, thus eliminating the requirement for a next-day injection. Udenyca Onbody significantly enhances the patient experience by ensuring prompt prophylactic treatment of chemotherapy-induced neutropenia while simultaneously decreasing clinic visits and fostering better adherence.
Which Industry Players Are Present In The Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Access The Complete Chemotherapy-Induced Neutropenia Treatment Market Report:
Which Region Commands The Largest Share Of The Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chemotherapy-Induced Neutropenia Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2026, By The Business Research Company
Chemotherapy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Chemotherapy Induced Anemia Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model